Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Acq. announced
Inv. presentation
Filed Chapter 11
Codiak BioSciences, Inc. (CDAK) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/02/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
03/27/2023 8-K Filed for Chapter 11
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process CAMBRIDGE, Mass., March 27, 2023 — Codiak BioSciences, Inc. , a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the Company has voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets which is intended to maximize the value of the Company. The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several parties. The Company expects to consummate a sale of the entire business or its core a..."
02/14/2023 SC 13G/A Flagship Ventures Fund V, L.P. reports a 11.8% stake in Codiak BioSciences, Inc.
02/14/2023 SC 13G ARMISTICE CAPITAL, LLC reports a 6.8% stake in CODIAK BIOSCIENCES, INC.
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/08/2023 SC 13G Laurion Capital Management LP reports a 5.5% stake in Codiak Biosciences, Inc.
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
09/20/2022 SC 13D ARCH Venture Fund VIII, L.P. reports a 24.7% stake in Codiak Biosciences, Inc.
09/12/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/30/2022 8-K Cost Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits  Interactiv...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring"
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/29/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/05/2022 8-K Quarterly results
04/29/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/10/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/10/2022 10-K Annual Report for the period ended December 31, 2021
03/10/2022 8-K Quarterly results
02/09/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/30/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Codiak BioSciences Announces FDA Clearance of IND for exoASO ™ -STAT6; Patient Dosing Expected 1H 2022 - Codiak's first engineered exosome therapeutic candidate for systemic administration - - Single agent anti-tumor effect observed in preclinical models via macrophage reprogramming - - Phase 1 trial will evaluate safety, tolerability, biomarkers and preliminary antitumor activity of exoASO-STAT6 in hepatocellular carcinomas - CAMBRIDGE, Mass., November 30, 2021 — Codiak BioSciences, Inc. , a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug Application for exoASO-STAT6. exoASO-STAT6 is Codiak's..."
11/17/2021 8-K Investor presentation
Docs: "Codiak Reports Positive Initial Data for exoSTING ™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts - exoSTING resulted in localized STING pathway activation and dose-dependent immune activation - - Intratumoral administration of exoSTING was well tolerated and demonstrated tumor retention, no systemic exposure to STING agonist, and in a subset of patients, tumor shrinkage in injected and distal non-injected lesions - - Data on objective response rate and recommended Phase 2 dose selection for expansion anticipated 1H 2022 - - Codiak to host conference call and webcast today at 8:00 am ET - CAMBRIDGE, Mass., November 16, 2021 — Codiak BioSciences, Inc. , a clinical-sta...",
"Presentation, by Codiak BioSciences, Inc"
11/16/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
11/16/2021 EFFECT Form EFFECT - Notice of Effectiveness:
11/04/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement, by and between Codiak BioSciences, Inc. and Jefferies LLC"
11/04/2021 S-3 Form S-3 - Registration statement under Securities Act of 1933:
11/04/2021 10-Q Quarterly Report for the period ended September 30, 2021
11/04/2021 8-K Quarterly results
Docs: "Codiak BioSciences Reports Third Quarter 2021 Financial Results and Recent Operational Progress"
11/02/2021 8-K Acquisition/merger/asset purchase announced
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish"
10/07/2021 8-K Termination of a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy